Skip to main content

Table 1 Gene expression signature for GC-sensitivity in CEM cells. (Signaling Network Genes)

From: Gene expression profiling of leukemic cells and primary thymocytes predicts a signature for apoptotic sensitivity to glucocorticoids

  

Sensitive

Sensitive

Sensitive

Sensitive

Resensitized

Resistant

Name

Description

C7–14 Dx

C7–14 Z

C1–6 Dx

C1–15 Z

C1–15 Dx+F

C1–15 Dx

AK2

adenylate kinase 2

-1.4

-1.7

-1.6

-1.6

-1.4

*

ARHGEF7

Rho guanine nucleotide exchange factor (GEF) 7

1.3

1.4

1.3

1.3

1.8

1.2

BCL2L11

BCL2-like 11 (apoptosis facilitator)

3.1

14.5

5.9

1.3

1.8

*

CALR

calreticulin

-1.9

-1.7

-1.6

-1.4

-1.6

-1.3

CDC6

CDC6 cell division cycle 6 homolog (S. cerevisiae)

-1.3

-1.2

-1.5

-1.3

-1.3

-1.3

DDIT4

DNA-damage-inducible transcript 4

4.4

3.4

2.5

1.2

4.4

1.5

FGFR1

fibroblast growth factor receptor 1

1.6

3.1

1.4

1.7

1.7

1.3

FKBP4

FK506 binding protein 4, 59 kDa

-1.9

-2.1

-1.3

-1.5

-1.6

*

FKBP5

FK506 binding protein 5

6.6

11.2

4.4

3.8

2.9

2.8

HDAC1

histone deacetylase 1

-1.4

-1.2

-1.2

-1.3

-1.2

-1.3

HRAS

v-Ha-ras Harvey rat sarcoma viral oncogene homolog

-1.3

-1.4

-1.3

-1.4

-1.4

*

ID1

inhibitor of DNA binding 1, dominant negative helix-loop-helix protein

-2.6

-1.7

-1.2

-1.9

-1.6

-1.4

IFRD1

interferon-related developmental regulator 1

-1.8

-1.2

-1.6

-1.6

-1.3

*

IL7R

interleukin 7 receptor

8.3

18.0

6.3

1.4

2.5

*

ITGA6

integrin, alpha 6

5.0

10.2

2.4

6.6

2.8

1.6

MAP4

microtubule-associated protein 4

-1.3

-1.8

-1.7

-1.3

-1.3

*

MT1A

metallothionein 1A (functional)

1.3

1.3

2.2

1.4

1.4

*

MTHFD1

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1

-1.4

-1.9

-1.5

-1.5

-1.2

*

MYC

v-myc myelocytomatosis viral oncogene homolog (avian)

-3.8

-4.6

-3.6

-1.4

-2.2

*

NFKBIA

nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha

3.0

3.4

2.8

1.9

1.5

1.3

NME1

non-metastatic cells 1, protein (NM23A) expressed in

-1.5

-2.2

-1.6

-1.4

-1.3

*

NR3C1

nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)

4.2

6.6

2.1

1.7

1.6

*

OGT

O-linked N-acetylglucosamine (GlcNAc) transferase

1.3

1.7

2.0

1.6

1.3

*

PIAS2

protein inhibitor of activated STAT, 2

1.2

1.4

1.5

2.0

1.3

*

PIK3R1

phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha)

2.5

2.4

1.7

2.0

1.9

*

RBMS1

RNA binding motif, single stranded interacting protein 1

1.4

2.0

1.7

1.6

1.5

1.6

SCARB1

scavenger receptor class B, member 1

-1.7

-2.2

-1.2

-1.5

-1.2

-1.3

SRM

spermidine synthase

-1.8

-3.3

-1.7

-1.4

-1.4

*

TAGLN2

transgelin 2

-1.4

-2.0

-1.3

-1.2

-1.2

*

TRAF3IP2

TRAF3 interacting protein 2

1.6

2.1

1.8

1.5

1.4

1.3

TSC22D3

TSC22 domain family, member 3

33.1

74.0

20.4

7.4

14.3

5.0

TXNIP

thioredoxin interacting protein

2.8

3.4

3.7

1.4

2.0

1.2

UBE2S

ubiquitin-conjugating enzyme E2S

-1.6

-1.6

-1.3

-1.6

-1.3

*

VCL

vinculin

1.8

1.6

1.9

1.3

1.5

*

YAF2

YY1 associated factor 2

1.8

2.4

1.6

1.7

1.3

1.6

  1. Regulated transcripts from vehicle or GC-treated samples were evaluated and compared using Spotfire® and Ingenuity® bioinformatics software. Selection criteria for each gene were as follows: probe called present (Methods) on the microarray and regulated ≥ 1.2-fold (net 20% change). GC-mediated transcripts regulated in common in the same direction among sensitive CEM-C7–14 Dex (C7–14 Dx) and CVZ (C7–14 Z), CEM-C1–6 (C1–6 Dx), CEM-C1–15 CVZ (C1–15 Z), and CEM-C1–15 Dex plus FSK (C1–15 Dx+F) cells were obtained. This comparison resulted in 96 regulated genes (see Additional file 1). This list was subsequently compared to Dex-treated resistant CEM-C1–15 cells (C1–15 Dx). Shown is a subset of 35 genes from the original 96 that could be linked via a signaling network (symbol, closed diamond in Additional file 1). Bold type indicates statistically significant regulation p ≤ 0.05 between means of vehicle vs. GC-treated. Symbol, asterisk = gene "absent" by selection criteria.
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us